Cursos

← vista completa

Publicado el 1 de junio de 2006 | http://doi.org/10.5867/medwave.2006.05.3383

Oncogénesis viral: VPH y cáncer cervicouterino

Viral oncogenesis: HPV and cervical cancer

Rodrigo Arriagada Demetrio

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Rodrigo Arriagada Demetrio

Becado de Oncología Ginecológica Hospital Clínico San Borja Arriarán
Facultad de Medicina, Universidad de Chile, Santiago, Chile

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Arriagada Demetrio R. Viral oncogenesis: HPV and cervical cancer. Medwave 2006;6(05):e3383 doi: 10.5867/medwave.2006.05.3383

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/06/2006

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Collier L. Viruses and cancer in humans. Human Virology 2000:49-56.
  2. Facultad de Medicina Norte. Apuntes de virología médica. Universidad de Chile.
  3. Vousden KH, Farrell PJ.Viruses and human cancer. Br Med Bull. 1994 Jul;50(3):560-81. | PubMed
  4. zur Haussen H. Viruses and human cancer. Science. 1991 Nov 22;254(5035):1167-73. | CrossRef | PubMed
  5. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;(31):14-9. | CrossRef
  6. Douglas RJ. Prophylactic human papillomavirus vaccines. Nat Cancer Inst Monogr 2003; (31): 111-6
  7. Stoler M. The Impact of Human Papillomavirus Biology on the Clinical Practice of Cervical Pathology. Pathology Case Reviews. May/June 2005; 10(3) | CrossRef
  8. IARC Working Group VPH.Human papillomavisruses. En: IARC Monogr carcinogenic risk to human. Vol 64. Lyon: 1995.
  9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol. 1999 Sep;189(1):12-9. | CrossRef
  10. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27. | CrossRef | PubMed
  11. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene. 2002 Sep 5;21(39):6041-8. | CrossRef | PubMed
  12. de Villiers EM. Heterogeneity of the human papillomavirus group. J Virol. 1989 Nov;63(11):4898-903. | PubMed
  13. Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol. 1992 Oct;73 (Pt 10):2653-60. | CrossRef | PubMed
  14. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 1995 Nov;13(16):1509-14. | CrossRef
  15. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A,et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996 May 1;219(1):37-44. | CrossRef | PubMed
  16. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995 Dec;69(12):7743-53. | PubMed
  17. Abbas K. Cellular and molecular immunology. W.B. Sanders, 1991.
  18. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells Eur J Immunol. 1993 Sep;23(9):2242-9. | CrossRef | PubMed
  19. Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, et al. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol. 1994 Jan;75 (Pt 1):157-64. | CrossRef | PubMed
  20. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 1991 Mar;181(1):62-9. | CrossRef
  21. Lowy RD, Frazer HI. Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003:31:1 1 1-116.
  22. Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future. Annals of Oncology 15: 197–200, 2004 | CrossRef | PubMed
  23. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol. 2004 Apr;2(4):343-7. | CrossRef | PubMed
  24. Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, et al Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy. Vaccine. 2004 Jul 29;22(21-22):2943-52. | CrossRef | PubMed
  25. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21;347(21):1645-51. | CrossRef | PubMed
  26. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1757-65. | CrossRef
  27. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005 May;6(5):271-8. | CrossRef